Pamiparib + Temozolomide
PNOC017
University of California, San Francisco · Phase 1 · Active, not recruiting · Enrollment 78
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
Pamiparib + Temozolomide
University of California, San Francisco · Phase 1 · Active, not recruiting · Enrollment 78
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.